Emerging Microbes and Infections (Jan 2020)
Non-active antibiotic and bacteriophage synergism to successfully treat recurrent urinary tract infection caused by extensively drug-resistant Klebsiella pneumoniae
- Juan Bao,
- Nannan Wu,
- Yigang Zeng,
- Liguang Chen,
- Linlin Li,
- Lan Yang,
- Yiyuan Zhang,
- Mingquan Guo,
- Lisha Li,
- Jie Li,
- Demeng Tan,
- Mengjun Cheng,
- Jingmin Gu,
- Jinghong Qin,
- Jiazheng Liu,
- Shiru Li,
- Guangqiang Pan,
- Xin Jin,
- Bangxin Yao,
- Xiaokui Guo,
- Tongyu Zhu,
- Shuai Le
Affiliations
- Juan Bao
- Shanghai Institute of Phage, Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
- Nannan Wu
- Shanghai Institute of Phage, Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
- Yigang Zeng
- Shanghai Institute of Phage, Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
- Liguang Chen
- Shanghai Institute of Phage, Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
- Linlin Li
- Shanghai Institute of Phage, Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
- Lan Yang
- Shanghai Institute of Phage, Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
- Yiyuan Zhang
- Shanghai Institute of Phage, Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
- Mingquan Guo
- Shanghai Institute of Phage, Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
- Lisha Li
- Department of Microbiology and Immunology, Institutes of Medical Sciences, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China
- Jie Li
- Shanghai Institute of Phage, Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
- Demeng Tan
- Shanghai Institute of Phage, Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
- Mengjun Cheng
- Shanghai Institute of Phage, Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
- Jingmin Gu
- Shanghai Institute of Phage, Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
- Jinghong Qin
- Shanghai Institute of Phage, Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
- Jiazheng Liu
- Department of Microbiology, Army Medical University, Chongqing, People’s Republic of China
- Shiru Li
- Department of Microbiology, Army Medical University, Chongqing, People’s Republic of China
- Guangqiang Pan
- Department of Pathology, The Second Affiliated Hospital of Army Medical University, Chongqing, People’s Republic of China
- Xin Jin
- Shanghai Institute of Phage, Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
- Bangxin Yao
- Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of China
- Xiaokui Guo
- Shanghai Institute of Phage, Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
- Tongyu Zhu
- Shanghai Institute of Phage, Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
- Shuai Le
- Shanghai Institute of Phage, Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
- DOI
- https://doi.org/10.1080/22221751.2020.1747950
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 771 – 774
Abstract
ABSTRACTWe report a case of a 63-year-old female patient who developed a recurrent urinary tract infection (UTI) with extensively drug-resistant Klebsiella pneumoniae (ERKp). In the initial two rounds of phage therapy, phage resistant mutants developed within days. Although ERKp strains were completely resistant to sulfamethoxazole-trimethoprim, the combination of sulfamethoxazole-trimethoprim with the phage cocktail inhibited the emergence of phage resistant mutant in vitro, and the UTI of patient was successfully cured by this combination. Thus, we propose that non-active antibiotic and bacteriophage synergism (NABS) might be an alternative strategy in personalized phage therapy.
Keywords
